CEO Today USA Awards

CEO Today USA Awards 2019 www.ceotodaymagazine.com - C A L I F O R N I A - 20 TODD ZAVODNICK CEO Dermavant Sciences Tell us a bit more about Dermavant and the innovative therapeutics that you develop. Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. Dermavant leverages the Roivant platform to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne. Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a differentiated therapeutic aryl hydrocarbon receptor modulating agent topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 7.5 million and 28 million people in the United States, respectively. Dermavant doesn’t simply focus on just a business mind or a scientific mind. We invite physicians who are participating in our clinical trials and/or key opinion leaders within the marketplace to interact with our employees. We also bring in patients because we know how important it is to listen to the people who are going to eventually use our products and understand this world that we all live in today. I am speaking of access - we must ensure that patients can and will receive our products, when and if they are approved. www.dermavant.com